Astellas Pharma Inc. Logo

Astellas Pharma Inc.

A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.

4503 | T

Overview

Corporate Details

ISIN(s):
JP3942400007
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. Formed in 2005 from the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., the company engages in the research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas focuses on addressing unmet medical needs in several therapeutic areas, with a primary emphasis on oncology. Its key areas of innovation also include gene therapy, immuno-oncology, regenerative medicine, and treatments for blindness and mitochondrial diseases. The company is committed to a stable supply of reliable medicines worldwide and stands at the forefront of healthcare change.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 03:29
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-06 03:26
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 310.0 KB
2025-07-31 08:30
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-07-31 04:04
Post-Annual General Meeting Information
訂正臨時報告書
Japanese 33.0 KB
2025-07-03 08:31
Registration Form
訂正発行登録書
Japanese 10.3 KB
2025-07-02 02:28
Post-Annual General Meeting Information
臨時報告書
Japanese 24.1 KB
2025-06-16 06:14
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.1 KB
2025-06-16 06:11
Registration Form
確認書
Japanese 8.7 KB
2025-06-16 06:09
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-02-04 07:47
Registration Form
訂正発行登録書
Japanese 9.9 KB
2025-02-04 07:40
Regulatory News Service
臨時報告書
Japanese 19.4 KB
2025-02-04 07:39
Regulatory News Service
臨時報告書
Japanese 20.9 KB
2024-11-06 05:52
Interim Report
確認書
Japanese 8.9 KB
2024-11-06 05:51
Interim Report
半期報告書-第20期(2024/04/01-2025/03/31)
Japanese 344.2 KB
2024-09-03 03:34
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 96.0 KB

Automate Your Workflow. Get a real-time feed of all Astellas Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Astellas Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Astellas Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.